|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity |
ISO |
benzoxazolone results in decreased activity of CYP1A2 protein |
CTD |
PMID:15916432 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
increases hydroxylation increases chemical synthesis multiple interactions increases abundance |
ISO EXP |
CYP2E1 protein results in increased hydroxylation of 6-hydroxychlorzoxazone CYP2E1 protein results in increased chemical synthesis of 6-hydroxychlorzoxazone [CYP2E1 mRNA results in increased metabolism of Chlorzoxazone] which results in increased chemical synthesis of 6-hydroxychlorzoxazone; [CYP2E1 protein results in increased metabolism of Chlorzoxazone] which results in increased chemical synthesis of 6-hydroxychlorzoxazone; Disulfiram inhibits the reaction [[CYP2E1 protein results in increased metabolism of Chlorzoxazone] which results in increased chemical synthesis of 6-hydroxychlorzoxazone]; Disulfiram inhibits the reaction [CYP2E1 protein results in increased chemical synthesis of 6-hydroxychlorzoxazone]; Fomepizole inhibits the reaction [CYP2E1 protein results in increased chemical synthesis of 6-hydroxychlorzoxazone] [CYP2E1 protein results in increased metabolism of Chlorzoxazone] which results in increased chemical synthesis of 6-hydroxychlorzoxazone; [Dextran Sulfate results in decreased activity of CYP2E1 protein] which results in decreased chemical synthesis of 6-hydroxychlorzoxazone [CYP2E1 protein results in increased metabolism of Chlorzoxazone] which results in increased abundance of 6-hydroxychlorzoxazone; [CYP2E1 protein results in increased metabolism of Chlorzoxazone] which results in increased chemical synthesis of 6-hydroxychlorzoxazone CYP2E1 protein results in increased abundance of 6-hydroxychlorzoxazone |
CTD |
PMID:12401345 PMID:15155557 PMID:19900514 PMID:21915887 PMID:23669205 PMID:26739624 PMID:28438436 PMID:29555536 PMID:30503582 PMID:31501917 More...
|
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
INS protein inhibits the reaction [stearic acid results in increased chemical synthesis of 6-hydroxychlorzoxazone] |
CTD |
PMID:26739624 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
|
G |
Alb |
albumin |
decreases response to substance |
ISO |
ALB protein results in decreased susceptibility to benoxaprofen |
CTD |
PMID:6699424 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alox12 |
arachidonate 12-lipoxygenase, 12S type |
decreases activity |
EXP |
benoxaprofen results in decreased activity of ALOX12 protein |
CTD |
PMID:3928952 |
|
NCBI chr10:54,958,263...54,970,542
Ensembl chr10:54,958,271...54,970,542
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions decreases activity |
ISO EXP |
[benoxaprofen results in decreased activity of ALOX5 protein] which results in decreased chemical synthesis of Leukotriene B4; [benoxaprofen results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:2724698 PMID:2849922 PMID:3020588 PMID:3928952 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression decreases activity |
EXP ISO |
benoxaprofen results in increased expression of CYP1A1 protein benoxaprofen results in decreased activity of CYP1A1 protein |
CTD |
PMID:2069584 PMID:33814510 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression |
EXP |
benoxaprofen results in increased expression of CYP1A2 protein |
CTD |
PMID:2069584 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
benoxaprofen results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp4a1 |
cytochrome P450, family 4, subfamily a, polypeptide 1 |
increases expression |
EXP |
benoxaprofen results in increased expression of CYP4A1 protein |
CTD |
PMID:2069584 |
|
NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464
|
|
G |
Ehhadh |
enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase |
increases expression |
EXP |
benoxaprofen results in increased expression of EHHADH protein |
CTD |
PMID:2069584 |
|
NCBI chr11:79,241,927...79,275,173
Ensembl chr11:79,241,938...79,275,188
|
|
G |
Gusb |
glucuronidase, beta |
increases secretion |
ISO |
benoxaprofen results in increased secretion of GUSB protein |
CTD |
PMID:6737371 |
|
NCBI chr12:26,701,191...26,714,718
Ensembl chr12:26,697,951...26,726,905
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
EXP |
benoxaprofen inhibits the reaction [LHB protein results in increased abundance of Pregnenolone]; benoxaprofen inhibits the reaction [LHB protein results in increased abundance of Testosterone] |
CTD |
PMID:6430271 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
affects response to substance |
ISO |
UGT1A3 affects the susceptibility to benoxaprofen |
CTD |
PMID:17880178 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
affects response to substance |
ISO |
UGT1A9 affects the susceptibility to benoxaprofen |
CTD |
PMID:17880178 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
affects response to substance increases glucuronidation |
ISO |
UGT2B7 affects the susceptibility to benoxaprofen UGT2B7 protein alternative form results in increased glucuronidation of benoxaprofen |
CTD |
PMID:8423545 PMID:17880178 |
|
NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
|
|
|
G |
Cyb5a |
cytochrome b5 type A |
multiple interactions |
ISO |
CYB5A protein promotes the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone] |
CTD |
PMID:15728263 |
|
NCBI chr18:78,213,067...78,245,677
Ensembl chr18:78,202,342...78,258,535 Ensembl chr18:78,202,342...78,258,535
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
affects metabolic processing |
EXP |
CYP1A1 protein affects the metabolism of Chlorzoxazone |
CTD |
PMID:15231049 PMID:15879494 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
affects metabolic processing increases hydroxylation |
ISO EXP |
CYP1A2 protein affects the metabolism of Chlorzoxazone CYP1A2 protein results in increased hydroxylation of Chlorzoxazone |
CTD |
PMID:11911841 PMID:14586387 PMID:15879494 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Chlorzoxazone results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
affects metabolic processing |
EXP |
CYP2B1 protein affects the metabolism of Chlorzoxazone |
CTD |
PMID:15879494 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
affects metabolic processing |
EXP |
CYP2C11 protein affects the metabolism of Chlorzoxazone |
CTD |
PMID:15879494 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2c13 |
cytochrome P450, family 2, subfamily c, polypeptide 13 |
affects metabolic processing |
EXP |
CYP2C13 protein affects the metabolism of Chlorzoxazone |
CTD |
PMID:15879494 |
|
NCBI chr 1:238,786,764...238,867,195
Ensembl chr 1:238,786,765...238,867,191
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
affects metabolic processing |
EXP |
CYP2C6V1 protein affects the metabolism of Chlorzoxazone |
CTD |
PMID:15879494 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
affects hydroxylation increases metabolic processing increases hydroxylation multiple interactions affects metabolic processing increases oxidation |
ISO EXP |
CYP2E1 protein affects the hydroxylation of Chlorzoxazone CYP2E1 protein results in increased metabolism of Chlorzoxazone CYP2E1 protein results in increased hydroxylation of Chlorzoxazone [CYP2E1 protein results in increased metabolism of Chlorzoxazone] which results in increased abundance of 6-hydroxychlorzoxazone; [CYP2E1 protein results in increased metabolism of Chlorzoxazone] which results in increased chemical synthesis of 6-hydroxychlorzoxazone; Resveratrol inhibits the reaction [CYP2E1 protein results in increased metabolism of Chlorzoxazone] CYP2E1 mRNA results in increased metabolism of Chlorzoxazone; CYP2E1 protein results in increased metabolism of Chlorzoxazone CYP2E1 protein affects the metabolism of Chlorzoxazone [CYP2E1 protein results in increased metabolism of Chlorzoxazone] which results in increased chemical synthesis of 6-hydroxychlorzoxazone; Imidazoles inhibits the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone]; Isoquinolines inhibits the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone]; Pyridines inhibits the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone]; Quinolines inhibits the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone] CYP2E1 protein results in increased oxidation of Chlorzoxazone [5-bromotryptamine analog results in decreased activity of CYP2E1 protein] which results in decreased metabolism of Chlorzoxazone; [5-chlorotryptamine analog results in decreased activity of CYP2E1 protein] which results in decreased metabolism of Chlorzoxazone; [5-fluoro-alpha-methyltryptamine results in decreased activity of CYP2E1 protein] which results in decreased metabolism of Chlorzoxazone; [5-fluorotryptamine analog results in decreased activity of CYP2E1 protein] which results in decreased metabolism of Chlorzoxazone; [5-methoxy-N,N-diisopropyltryptamine analog results in decreased activity of CYP2E1 protein] which results in decreased metabolism of Chlorzoxazone; [5-methyltryptamine analog results in decreased activity of CYP2E1 protein] which results in decreased metabolism of Chlorzoxazone; [7-methyltryptamine analog results in decreased activity of CYP2E1 protein] which results in decreased metabolism of Chlorzoxazone; [Chlormethiazole results in decreased activity of CYP2E1 protein] which results in decreased metabolism of Chlorzoxazone; [Chlorzoxazone results in decreased activity of CYP2E1 protein] which results in decreased degradation of vanoxerine; [CYP2E1 mRNA results in increased metabolism of Chlorzoxazone] which results in increased chemical synthesis of 6-hydroxychlorzoxazone; [CYP2E1 protein results in increased metabolism of Chlorzoxazone] which results in increased chemical synthesis of 6-hydroxychlorzoxazone; [indopan analog results in decreased activity of CYP2E1 protein] which results in decreased metabolism of Chlorzoxazone; [indopan results in decreased activity of CYP2E1 protein] which results in decreased metabolism of Chlorzoxazone; [Methoxydimethyltryptamines analog results in decreased activity of CYP2E1 protein] which results in decreased metabolism of Chlorzoxazone; [N,N-diallyl-5-methoxytryptamine results in decreased activity of CYP2E1 protein] which results in decreased metabolism of Chlorzoxazone; [N,N-diisopropyltryptamine analog results in decreased activity of CYP2E1 protein] which results in decreased metabolism of Chlorzoxazone; [Tryptamines analog results in decreased activity of CYP2E1 protein] which results in decreased metabolism of Chlorzoxazone; Carbaryl inhibits the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone]; chlorfluazuron inhibits the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone]; Chlorpyrifos inhibits the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone]; CYB5A protein promotes the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone]; cypermethrin inhibits the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone]; Disulfiram inhibits the reaction [[CYP2E1 protein results in increased metabolism of Chlorzoxazone] which results in increased chemical synthesis of 6-hydroxychlorzoxazone]; Disulfiram inhibits the reaction [CYP2E1 protein results in increased metabolism of Chlorzoxazone]; Fenitrothion inhibits the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone]; fenvalerate inhibits the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone]; Fomepizole inhibits the reaction [CYP2E1 protein results in increased metabolism of Chlorzoxazone]; isoproturon inhibits the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone]; Malathion inhibits the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone]; perfluorooctane sulfonic acid inhibits the reaction [CYP2E1 protein results in increased oxidation of Chlorzoxazone]; phenthoate inhibits the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone]; profenofos inhibits the reaction [CYP2E1 protein results in increased hydroxylation of Chlorzoxazone] |
CTD |
PMID:7747284 PMID:8558417 PMID:8858968 PMID:9817075 PMID:9825833 PMID:10207612 PMID:10463382 PMID:11502731 PMID:11911841 PMID:12401345 PMID:12433797 PMID:12464242 PMID:12690492 PMID:12818727 PMID:14586387 PMID:15155557 PMID:15205388 PMID:15231049 PMID:15255802 PMID:15327588 PMID:15370959 PMID:15576447 PMID:15618748 PMID:15626586 PMID:15728263 PMID:15802389 PMID:15879494 PMID:16124035 PMID:17565714 PMID:21600194 PMID:21915887 PMID:21964418 PMID:22634058 PMID:23669205 PMID:25956474 PMID:26599973 PMID:26739624 PMID:28438436 PMID:28762043 PMID:29555536 PMID:30503582 PMID:31501917 More...
|
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
affects metabolic processing |
EXP |
CYP3A2 protein affects the metabolism of Chlorzoxazone |
CTD |
PMID:15879494 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
increases hydroxylation affects metabolic processing |
EXP |
CYP3A23-3A1 protein results in increased hydroxylation of Chlorzoxazone CYP3A23-3A1 protein affects the metabolism of Chlorzoxazone |
CTD |
PMID:11911841 PMID:15879494 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
affects metabolic processing |
EXP |
CYP3A9 protein affects the metabolism of Chlorzoxazone |
CTD |
PMID:15879494 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
INS protein inhibits the reaction [stearic acid results in increased hydroxylation of Chlorzoxazone] |
CTD |
PMID:26739624 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Kcnn4 |
potassium calcium-activated channel subfamily N member 4 |
increases activity |
ISO |
Chlorzoxazone results in increased activity of KCNN4 protein |
CTD |
PMID:14985237 |
|
NCBI chr 1:79,956,380...79,974,354
Ensembl chr 1:79,959,322...79,974,340
|
|
G |
Nat2 |
N-acetyltransferase 2 |
affects metabolic processing |
ISO |
NAT2 protein affects the metabolism of Chlorzoxazone |
CTD |
PMID:14586387 |
|
NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520
|
|
G |
Xdh |
xanthine dehydrogenase |
affects metabolic processing |
ISO |
XDH protein affects the metabolism of Chlorzoxazone |
CTD |
PMID:14586387 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity |
ISO |
iloperidone results in decreased activity of ABCB11 protein |
CTD |
PMID:23956101 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity decreases expression |
ISO |
iloperidone results in decreased activity of CYP3A4 protein iloperidone results in decreased expression of CYP3A4 mRNA |
CTD |
PMID:32941854 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects abundance multiple interactions increases export increases transport affects response to substance decreases activity |
ISO EXP |
ABCB1 gene polymorphism affects the abundance of Paliperidone Palmitate; ABCB1 protein affects the abundance of Paliperidone Palmitate Cyclosporine inhibits the reaction [ABCB1A protein results in increased export of Paliperidone Palmitate] ABCB1A protein results in increased transport of Paliperidone Palmitate ABCB1A protein affects the susceptibility to Paliperidone Palmitate Paliperidone Palmitate results in decreased activity of ABCB1 protein Paliperidone Palmitate inhibits the reaction [ABCB1 protein results in decreased export of Doxorubicin] ABCB1 protein results in increased transport of Paliperidone Palmitate |
CTD |
PMID:15502009 PMID:16118767 PMID:16810505 PMID:16936711 PMID:17541883 PMID:22691713 More...
|
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
affects response to substance |
ISO |
ABCB1B protein affects the susceptibility to Paliperidone Palmitate |
CTD |
PMID:15502009 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
decreases activity |
ISO |
Paliperidone Palmitate results in decreased activity of ABCB4 protein |
CTD |
PMID:28437613 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
Paliperidone Palmitate inhibits the reaction [ABCG2 protein results in increased transport of Mitoxantrone] |
CTD |
PMID:18834354 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression |
EXP |
Paliperidone Palmitate results in increased expression of BDNF mRNA |
CTD |
PMID:21220416 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
affects abundance |
ISO |
CYP2D6 gene polymorphism affects the abundance of Paliperidone Palmitate; CYP2D6 protein affects the abundance of Paliperidone Palmitate |
CTD |
PMID:10639689 PMID:15089809 PMID:17541883 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions affects binding |
ISO EXP |
Paliperidone Palmitate binds to and results in decreased activity of DRD2 protein Paliperidone Palmitate binds to DRD2 protein |
CTD |
PMID:19713555 PMID:22437487 |
|
NCBI chr 8:49,708,903...49,772,888
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Fads2 |
fatty acid desaturase 2 |
increases expression multiple interactions |
EXP |
Paliperidone Palmitate results in increased expression of FADS2 mRNA [Paliperidone Palmitate results in increased expression of FADS2 mRNA] which results in increased abundance of Fatty Acids, Unsaturated |
CTD |
PMID:21458237 |
|
NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789
|
|
G |
Htr2a |
5-hydroxytryptamine receptor 2A |
affects binding multiple interactions |
ISO EXP |
Paliperidone Palmitate binds to HTR2A protein Paliperidone Palmitate binds to and results in decreased activity of HTR2A protein |
CTD |
PMID:7520908 PMID:19713555 PMID:22437487 |
|
NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928
|
|
G |
Htr7 |
5-hydroxytryptamine receptor 7 |
multiple interactions |
ISO |
[Paliperidone Palmitate binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Paliperidone Palmitate binds to and results in decreased activity of HTR7 protein |
CTD |
PMID:18996971 PMID:19509219 PMID:20827463 |
|
NCBI chr 1:233,636,442...233,761,063
Ensembl chr 1:233,636,452...233,760,626
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
Paliperidone Palmitate results in increased expression of IL1A mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
Paliperidone Palmitate results in increased expression of IL1B mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il24 |
interleukin 24 |
increases expression |
ISO |
Paliperidone Palmitate results in increased expression of IL24 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Paliperidone Palmitate results in decreased activity of KCNH2 protein |
CTD |
PMID:21394035 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Prl |
prolactin |
increases expression |
ISO |
Paliperidone Palmitate results in increased expression of PRL protein |
CTD |
PMID:17460786 PMID:19825908 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions decreases activity |
ISO |
[phosalone co-treated with Verapamil] inhibits the reaction [ABCB1 protein results in increased transport of calcein AM]; [phosalone co-treated with Verapamil] results in decreased activity of ABCB1 protein; Diazinon promotes the reaction [phosalone inhibits the reaction [ABCB1 protein results in increased transport of calcein AM]]; Diazinon promotes the reaction [phosalone results in decreased activity of ABCB1 protein]; Endosulfan inhibits the reaction [phosalone inhibits the reaction [ABCB1 protein results in increased transport of calcein AM]]; Endosulfan inhibits the reaction [phosalone results in decreased activity of ABCB1 protein]; phosalone inhibits the reaction [ABCB1 protein results in increased transport of calcein AM]; phosalone inhibits the reaction [Endosulfan inhibits the reaction [ABCB1 protein results in increased transport of calcein AM]]; phosalone inhibits the reaction [Endosulfan results in decreased activity of ABCB1 protein]; phosalone inhibits the reaction [propiconazole inhibits the reaction [ABCB1 protein results in increased transport of calcein AM]]; phosalone inhibits the reaction [propiconazole results in decreased activity of ABCB1 protein]; propiconazole inhibits the reaction [phosalone inhibits the reaction [ABCB1 protein results in increased transport of calcein AM]]; propiconazole inhibits the reaction [phosalone results in decreased activity of ABCB1 protein] |
CTD |
PMID:21783720 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
ISO |
phosalone metabolite results in decreased activity of ACHE protein |
CTD |
PMID:33844597 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
Dihydrotestosterone inhibits the reaction [phosalone results in increased activity of AR protein]; phosalone inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein] |
CTD |
PMID:15064155 PMID:33049310 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[Omite co-treated with Diphenylamine co-treated with phosalone co-treated with Captan co-treated with N-dichlorofluoromethylthio-N',N'-dimethyl-N-p-tolylsulfamide] results in increased expression of CYP3A4 mRNA |
CTD |
PMID:25028461 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
phosalone binds to and results in increased activity of ESR1 protein |
CTD |
PMID:33049310 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Gal |
galanin and GMAP prepropeptide |
multiple interactions increases activity |
EXP |
Ellagic Acid inhibits the reaction [phosalone results in increased activity of GAL protein] |
CTD |
PMID:27965107 |
|
NCBI chr 1:200,650,439...200,655,302
Ensembl chr 1:200,650,439...200,654,959
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression |
EXP |
Ellagic Acid inhibits the reaction [phosalone results in increased expression of IL1B protein] |
CTD |
PMID:27965107 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [phosalone results in increased expression of IL6 protein] |
CTD |
PMID:27965107 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
increases expression multiple interactions |
EXP |
phosalone results in increased expression of MAPK14 protein Ellagic Acid inhibits the reaction [phosalone results in increased expression of MAPK14 protein] |
CTD |
PMID:27965107 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
phosalone binds to and results in increased activity of NR1I2 protein [Omite co-treated with Diphenylamine co-treated with phosalone co-treated with Captan co-treated with N-dichlorofluoromethylthio-N',N'-dimethyl-N-p-tolylsulfamide] results in increased activity of NR1I2 protein; phosalone binds to and results in increased activity of NR1I2 protein |
CTD |
PMID:21115097 PMID:25028461 PMID:33049310 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases activity |
ISO |
phosalone results in increased activity of NR1I3 protein |
CTD |
PMID:20143881 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
phosalone binds to and results in increased activity of PPARG protein |
CTD |
PMID:33049310 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Rara |
retinoic acid receptor, alpha |
increases activity |
ISO |
phosalone results in increased activity of RARA protein |
CTD |
PMID:20143881 |
|
NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions increases expression |
EXP |
Ellagic Acid inhibits the reaction [phosalone results in increased expression of RB1 mRNA]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of RB1 protein] phosalone results in increased expression of RB1 mRNA; phosalone results in increased expression of RB1 protein |
CTD |
PMID:27965107 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions increases expression |
EXP |
Ellagic Acid inhibits the reaction [phosalone results in increased expression of RELA protein] |
CTD |
PMID:27965107 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Si |
sucrase-isomaltase |
decreases activity |
EXP |
phosalone results in decreased activity of SI protein |
CTD |
PMID:92405 |
|
NCBI chr 2:157,505,893...157,586,228
Ensembl chr 2:157,506,342...157,585,260
|
|
G |
Tert |
telomerase reverse transcriptase |
decreases activity multiple interactions |
EXP |
phosalone results in decreased activity of TERT protein Ellagic Acid inhibits the reaction [phosalone results in decreased activity of TERT protein] |
CTD |
PMID:27965107 |
|
NCBI chr 1:29,637,213...29,659,509
Ensembl chr 1:29,637,506...29,659,561
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
EXP |
Ellagic Acid inhibits the reaction [phosalone results in increased expression of TNF protein] |
CTD |
PMID:27965107 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
increases expression multiple interactions |
EXP |
phosalone results in increased expression of TP53 mRNA; phosalone results in increased expression of TP53 protein Ellagic Acid inhibits the reaction [phosalone results in increased expression of TP53 mRNA]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of TP53 protein] |
CTD |
PMID:27965107 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects abundance multiple interactions increases export increases transport decreases activity affects response to substance increases response to substance |
ISO EXP |
ABCB1 gene polymorphism affects the abundance of Risperidone; ABCB1 protein affects the abundance of Risperidone Cyclosporine inhibits the reaction [ABCB1A protein results in increased export of Risperidone] ABCB1A protein results in increased transport of Risperidone Risperidone results in decreased activity of ABCB1 protein ABCB1A protein affects the susceptibility to Risperidone ABCB1 protein results in increased transport of Risperidone Risperidone inhibits the reaction [ABCB1 protein results in decreased export of Doxorubicin] ABCB1 protein results in increased susceptibility to Risperidone ABCB1 gene polymorphism affects the susceptibility to Risperidone; ABCB1 protein affects the susceptibility to Risperidone |
CTD |
PMID:15502009 PMID:16118767 PMID:16810505 PMID:16936711 PMID:17054409 PMID:17541883 PMID:18708991 PMID:19997080 PMID:20563569 PMID:21449914 PMID:22623266 PMID:22691713 More...
|
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
affects response to substance |
ISO |
ABCB1B protein affects the susceptibility to Risperidone |
CTD |
PMID:15502009 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
Risperidone inhibits the reaction [ABCG2 protein results in increased transport of Mitoxantrone]; Risperidone inhibits the reaction [ABCG2 protein results in increased uptake of estrone sulfate] |
CTD |
PMID:18834354 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions increases expression |
ISO |
Berberine inhibits the reaction [Risperidone results in increased expression of ADIPOQ mRNA] |
CTD |
PMID:20564506 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
decreases expression multiple interactions |
EXP ISO |
Risperidone results in decreased expression of BDNF mRNA BDNF gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein] Risperidone inhibits the reaction [Rotenone results in decreased expression of BDNF mRNA] |
CTD |
PMID:12393228 PMID:17442543 PMID:19997080 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Calm2 |
calmodulin 2 |
increases expression |
EXP |
Risperidone results in increased expression of CALM2 mRNA |
CTD |
PMID:19289156 |
|
NCBI chr 6:7,091,624...7,104,284
Ensembl chr 6:7,091,567...7,104,287
|
|
G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
decreases expression |
EXP |
Risperidone results in decreased expression of CAMK2A protein |
CTD |
PMID:19289156 |
|
NCBI chr18:54,378,642...54,441,120
Ensembl chr18:54,378,784...54,438,994
|
|
G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
decreases expression |
EXP |
Risperidone results in decreased expression of CAMK4 protein |
CTD |
PMID:19289156 |
|
NCBI chr18:24,582,988...24,811,918
Ensembl chr18:24,585,269...24,802,487
|
|
G |
Camkk1 |
calcium/calmodulin-dependent protein kinase kinase 1 |
decreases expression |
EXP |
Risperidone results in decreased expression of CAMKK1 protein |
CTD |
PMID:19289156 |
|
NCBI chr10:57,637,335...57,660,498
Ensembl chr10:57,637,391...57,660,498
|
|
G |
Camkk2 |
calcium/calmodulin-dependent protein kinase kinase 2 |
decreases expression |
EXP |
Risperidone results in decreased expression of CAMKK2 protein |
CTD |
PMID:19289156 |
|
NCBI chr12:33,791,023...33,845,000
Ensembl chr12:33,791,052...33,843,279
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO |
Palmitic Acid promotes the reaction [Risperidone results in increased activity of CASP3 protein] |
CTD |
PMID:22700542 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions increases activity |
ISO |
Palmitic Acid promotes the reaction [Risperidone results in increased activity of CASP7 protein] |
CTD |
PMID:22700542 |
|
NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions increases expression |
ISO |
Berberine inhibits the reaction [Risperidone results in increased expression of CEBPA mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of CEBPA protein] Risperidone results in increased expression of CEBPA mRNA; Risperidone results in increased expression of CEBPA protein |
CTD |
PMID:20564506 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Chrm4 |
cholinergic receptor, muscarinic 4 |
affects response to substance |
ISO |
CHRM4 affects the susceptibility to Risperidone |
CTD |
PMID:21269601 |
|
NCBI chr 3:77,893,425...77,901,166
Ensembl chr 3:77,893,425...77,901,159
|
|
G |
Comt |
catechol-O-methyltransferase |
increases expression |
EXP |
Risperidone results in increased expression of COMT mRNA |
CTD |
PMID:15964593 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Crh |
corticotropin releasing hormone |
decreases expression |
ISO |
Risperidone results in decreased expression of CRH mRNA |
CTD |
PMID:16205782 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions increases expression |
EXP |
DRD2 protein affects the reaction [Risperidone results in increased expression of CTNNB1 protein] |
CTD |
PMID:16144542 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
affects metabolic processing increases metabolic processing increases response to substance affects response to substance decreases hydroxylation decreases metabolic processing affects abundance multiple interactions |
ISO |
CYP2D6 gene polymorphism affects the metabolism of Risperidone; CYP2D6 protein affects the metabolism of Risperidone CYP2D6 protein results in increased metabolism of Risperidone CYP2D6 protein results in increased susceptibility to Risperidone CYP2D6 gene polymorphism affects the susceptibility to Risperidone; CYP2D6 protein polymorphism affects the susceptibility to Risperidone CYP2D6 gene polymorphism results in decreased hydroxylation of Risperidone CYP2D6 gene polymorphism results in decreased metabolism of Risperidone CYP2D6 gene polymorphism affects the abundance of Risperidone; CYP2D6 protein affects the abundance of Risperidone CYP2D6 gene polymorphism affects the metabolism of and affects the abundance of Risperidone; CYP2D6 protein affects the metabolism of and affects the abundance of Risperidone |
CTD |
PMID:10639689 PMID:15089809 PMID:15260906 PMID:15565299 PMID:15669884 PMID:16044105 PMID:17224713 PMID:17541883 PMID:18708991 PMID:19387994 PMID:20332423 PMID:20563569 PMID:21449914 PMID:22623266 PMID:22745940 PMID:23609392 More...
|
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions affects response to substance |
ISO |
N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Risperidone promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; Risperidone promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA] CYP3A4 gene polymorphism affects the susceptibility to Risperidone; CYP3A4 protein affects the susceptibility to Risperidone |
CTD |
PMID:19395426 PMID:21402137 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
affects abundance increases metabolic processing |
ISO |
CYP3A5 gene polymorphism affects the abundance of Risperidone; CYP3A5 protein affects the abundance of Risperidone CYP3A5 protein results in increased metabolism of Risperidone |
CTD |
PMID:18708991 PMID:20332423 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions affects binding increases response to substance affects response to substance |
ISO EXP |
Risperidone binds to and results in decreased activity of DRD2 protein Risperidone binds to DRD2 protein [Risperidone binds to and results in decreased activity of DRD2 protein] which results in increased expression of PPP3CA protein; DRD2 protein affects the reaction [Risperidone results in increased expression of CTNNB1 protein]; DRD2 protein affects the reaction [Risperidone results in increased expression of DVL3 protein]; DRD2 protein affects the reaction [Risperidone results in increased expression of GSK3A protein]; DRD2 protein affects the reaction [Risperidone results in increased expression of GSK3B protein]; Risperidone binds to and results in decreased activity of DRD2 protein; Risperidone inhibits the reaction [Apomorphine binds to and results in increased activity of DRD2 protein]; Risperidone promotes the reaction [Dopamine binds to DRD2 protein] DRD2 gene polymorphism results in increased susceptibility to Risperidone; DRD2 gene SNP results in increased susceptibility to Risperidone; DRD2 protein results in increased susceptibility to Risperidone DRD2 gene polymorphism affects the susceptibility to Risperidone |
CTD |
PMID:1380082 PMID:7520908 PMID:8804920 PMID:10831489 PMID:12191584 PMID:15710053 PMID:15716360 PMID:16033416 PMID:16144542 PMID:16513859 PMID:18058087 PMID:19339912 PMID:19640686 PMID:19910723 PMID:20361897 PMID:20375926 PMID:21869689 PMID:22437487 PMID:22967779 More...
|
|
NCBI chr 8:49,708,903...49,772,888
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Drd3 |
dopamine receptor D3 |
increases response to substance |
ISO |
DRD3 gene SNP results in increased susceptibility to Risperidone; DRD3 protein results in increased susceptibility to Risperidone |
CTD |
PMID:19506579 PMID:19997080 |
|
NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596
|
|
G |
Dvl3 |
dishevelled segment polarity protein 3 |
multiple interactions increases expression |
EXP |
DRD2 protein affects the reaction [Risperidone results in increased expression of DVL3 protein] |
CTD |
PMID:16144542 |
|
NCBI chr11:80,365,446...80,382,641
Ensembl chr11:80,366,117...80,382,462
|
|
G |
Egr1 |
early growth response 1 |
decreases expression |
EXP |
Risperidone results in decreased expression of EGR1 protein |
CTD |
PMID:17028028 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Egr2 |
early growth response 2 |
decreases expression multiple interactions |
EXP ISO |
Risperidone results in decreased expression of EGR2 protein Risperidone inhibits the reaction [Toluene promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of EGR2 protein]] |
CTD |
PMID:17028028 PMID:32980479 |
|
NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
increases phosphorylation |
EXP |
Risperidone results in increased phosphorylation of ERBB2 protein |
CTD |
PMID:26961615 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
multiple interactions |
EXP |
Risperidone results in increased expression of and results in increased phosphorylation of ERBB4 protein |
CTD |
PMID:26961615 |
|
NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595
|
|
G |
Fads2 |
fatty acid desaturase 2 |
increases expression multiple interactions |
EXP |
Risperidone results in increased expression of FADS2 mRNA [Risperidone results in increased expression of FADS2 mRNA] which results in increased abundance of Fatty Acids, Unsaturated |
CTD |
PMID:21458237 |
|
NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions increases expression |
ISO |
Berberine inhibits the reaction [Risperidone results in increased expression of FAS mRNA] |
CTD |
PMID:20564506 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
EXP ISO |
Risperidone promotes the reaction [Rotenone results in increased expression of FOS mRNA] Dronabinol inhibits the reaction [Risperidone results in increased expression of FOS protein]; Risperidone inhibits the reaction [Toluene promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of FOS protein]] Risperidone results in increased expression of FOS mRNA |
CTD |
PMID:11516571 PMID:17442543 PMID:28272498 PMID:32980479 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
affects expression |
ISO |
Risperidone affects the expression of FSHB protein |
CTD |
PMID:18838228 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Gsk3a |
glycogen synthase kinase 3 alpha |
increases expression multiple interactions |
EXP |
Risperidone results in increased expression of GSK3A protein DRD2 protein affects the reaction [Risperidone results in increased expression of GSK3A protein] |
CTD |
PMID:16144542 |
|
NCBI chr 1:80,815,843...80,825,732
Ensembl chr 1:80,815,850...80,825,802
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions increases expression |
EXP |
DRD2 protein affects the reaction [Risperidone results in increased expression of GSK3B protein] |
CTD |
PMID:16144542 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
increases expression |
ISO |
Risperidone results in increased expression of HMGCR mRNA |
CTD |
PMID:17052361 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Homer1 |
homer scaffold protein 1 |
increases expression |
EXP |
Risperidone results in increased expression of HOMER1 mRNA |
CTD |
PMID:20147574 |
|
NCBI chr 2:24,542,777...24,645,715
Ensembl chr 2:24,543,093...24,644,785
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
increases response to substance multiple interactions |
EXP |
HTR1A protein results in increased susceptibility to Risperidone N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide inhibits the reaction [HTR1A protein results in increased susceptibility to Risperidone] |
CTD |
PMID:17530476 |
|
NCBI chr 2:36,694,174...36,695,442
Ensembl chr 2:36,694,174...36,695,442
|
|
G |
Htr2a |
5-hydroxytryptamine receptor 2A |
increases response to substance affects binding multiple interactions affects response to substance |
ISO EXP |
HTR2A gene SNP results in increased susceptibility to Risperidone; HTR2A protein results in increased susceptibility to Risperidone Risperidone binds to HTR2A protein Risperidone binds to and results in decreased activity of HTR2A protein; Risperidone inhibits the reaction [Ketanserin binds to HTR2A protein] HTR2A gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]; Risperidone binds to and results in decreased activity of HTR2A protein HTR2A protein affects the susceptibility to Risperidone |
CTD |
PMID:7520908 PMID:11927170 PMID:12191584 PMID:16314884 PMID:16948927 PMID:19997080 PMID:22437487 More...
|
|
NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928
|
|
G |
Htr2c |
5-hydroxytryptamine receptor 2C |
affects response to substance multiple interactions increases response to substance |
ISO |
HTR2C gene polymorphism affects the susceptibility to Risperidone; HTR2C protein affects the susceptibility to Risperidone HTR2C gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein] HTR2C protein results in increased susceptibility to Risperidone |
CTD |
PMID:19142101 PMID:19997080 |
|
NCBI chr X:110,640,777...110,870,288
Ensembl chr X:110,641,153...110,870,287
|
|
G |
Htr6 |
5-hydroxytryptamine receptor 6 |
multiple interactions |
ISO |
HTR6 gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein] |
CTD |
PMID:19997080 |
|
NCBI chr 5:151,295,269...151,312,853
Ensembl chr 5:151,296,662...151,311,912
|
|
G |
Htr7 |
5-hydroxytryptamine receptor 7 |
multiple interactions |
ISO |
2-((2-(dimethylamino)ethyl)thio)-3-phenylquinoline inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]; [Risperidone binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Clozapine inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]; Cyproheptadine inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]; mesulergine inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]; Mianserin inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]; Risperidone binds to and results in decreased activity of HTR7 protein; SB 269970 inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein] |
CTD |
PMID:18996971 PMID:19509219 PMID:20827463 |
|
NCBI chr 1:233,636,442...233,761,063
Ensembl chr 1:233,636,452...233,760,626
|
|
G |
Inha |
inhibin subunit alpha |
multiple interactions |
ISO |
Risperidone results in increased expression of [INHA protein binds to INHBB protein] |
CTD |
PMID:18838228 |
|
NCBI chr 9:76,994,465...76,997,366
Ensembl chr 9:76,993,589...76,997,248
|
|
G |
Inhbb |
inhibin subunit beta B |
multiple interactions |
ISO |
Risperidone results in increased expression of [INHA protein binds to INHBB protein] |
CTD |
PMID:18838228 |
|
NCBI chr13:30,530,860...30,536,566
Ensembl chr13:30,530,860...30,537,832
|
|
G |
Ins2 |
insulin 2 |
increases expression |
ISO |
Risperidone results in increased expression of INS protein |
CTD |
PMID:11927762 PMID:16601995 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions |
ISO |
Risperidone inhibits the reaction [KCNH2 protein results in increased transport of Thallium] |
CTD |
PMID:21158687 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions increases expression |
ISO |
Berberine inhibits the reaction [Risperidone results in increased expression of LDLR mRNA] |
CTD |
PMID:20564506 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Maoa |
monoamine oxidase A |
affects response to substance increases response to substance |
ISO |
MAOA gene polymorphism affects the susceptibility to Risperidone MAOA protein results in increased susceptibility to Risperidone |
CTD |
PMID:22544010 |
|
NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593
|
|
G |
Maob |
monoamine oxidase B |
increases expression |
EXP |
Risperidone results in increased expression of MAOB mRNA |
CTD |
PMID:15964593 |
|
NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003
|
|
G |
Map2 |
microtubule-associated protein 2 |
increases expression |
EXP |
Risperidone results in increased expression of MAP2 mRNA |
CTD |
PMID:15079866 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Ngfr |
nerve growth factor receptor |
decreases expression |
EXP |
Risperidone results in decreased expression of NGFR mRNA |
CTD |
PMID:12111809 PMID:16513140 |
|
NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Risperidone promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; Risperidone promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:21402137 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nrg1 |
neuregulin 1 |
increases expression |
EXP |
Risperidone results in increased expression of NRG1 protein |
CTD |
PMID:26961615 |
|
NCBI chr16:59,250,658...60,303,024
Ensembl chr16:59,250,854...60,296,884
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression multiple interactions |
ISO |
Risperidone results in increased expression of PPARG mRNA; Risperidone results in increased expression of PPARG protein Berberine inhibits the reaction [Risperidone results in increased expression of PPARG mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of PPARG protein] |
CTD |
PMID:20564506 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppp3ca |
protein phosphatase 3 catalytic subunit alpha |
multiple interactions decreases expression |
EXP |
[Risperidone binds to and results in decreased activity of DRD2 protein] which results in increased expression of PPP3CA protein Risperidone results in decreased expression of PPP3CA mRNA; Risperidone results in decreased expression of PPP3CA protein |
CTD |
PMID:16033416 |
|
NCBI chr 2:225,165,981...225,440,978
Ensembl chr 2:225,165,766...225,438,974
|
|
G |
Prl |
prolactin |
multiple interactions increases secretion increases expression |
ISO EXP |
[Risperidone co-treated with Clozapine] results in increased expression of PRL protein; Aripiprazole inhibits the reaction [Risperidone results in increased secretion of PRL protein]; BDNF gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]; HTR2A gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]; HTR2C gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]; HTR6 gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein] Risperidone inhibits the reaction [Dopamine results in decreased secretion of PRL protein] |
CTD |
PMID:1380082 PMID:9696519 PMID:9989566 PMID:10084644 PMID:11048906 PMID:11155212 PMID:11561931 PMID:11927762 PMID:12902212 PMID:12974991 PMID:15206663 PMID:15286066 PMID:15289996 PMID:15669890 PMID:15960571 PMID:16379509 PMID:16730335 PMID:17224713 PMID:18063941 PMID:18080171 PMID:18466271 PMID:18562423 PMID:18759643 PMID:18838228 PMID:19653986 PMID:19825908 PMID:19906340 PMID:19997080 PMID:20373475 PMID:20661022 PMID:20814333 More...
|
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Rgs2 |
regulator of G-protein signaling 2 |
increases expression |
EXP |
Risperidone results in increased expression of RGS2 mRNA |
CTD |
PMID:11516571 |
|
NCBI chr13:55,799,749...55,802,354
Ensembl chr13:55,798,829...55,802,385
|
|
G |
S100b |
S100 calcium binding protein B |
increases secretion |
EXP |
Risperidone results in increased secretion of S100B protein |
CTD |
PMID:18421423 |
|
NCBI chr20:12,372,866...12,381,619
Ensembl chr20:12,372,881...12,394,743
|
|
G |
Slc17a6 |
solute carrier family 17 member 6 |
increases expression |
ISO |
Risperidone results in increased expression of SLC17A6 mRNA; Risperidone results in increased expression of SLC17A6 protein |
CTD |
PMID:18155072 |
|
NCBI chr 1:101,212,489...101,252,543
Ensembl chr 1:101,212,489...101,252,542
|
|
G |
Snap25 |
synaptosome associated protein 25 |
affects response to substance |
ISO |
SNAP25 gene SNP affects the susceptibility to Risperidone |
CTD |
PMID:15823421 |
|
NCBI chr 3:124,041,898...124,123,761
Ensembl chr 3:124,041,898...124,123,760
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions increases expression |
EXP |
Risperidone inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of SOD1 mRNA]; Risperidone inhibits the reaction [Haloperidol results in decreased expression of SOD1 protein] Risperidone results in increased expression of SOD1 mRNA |
CTD |
PMID:12111809 PMID:12752374 PMID:16564057 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions increases expression |
ISO |
Berberine inhibits the reaction [Risperidone results in increased expression of SREBF1 mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of SREBF1 protein] Risperidone results in increased expression of SREBF1 mRNA; Risperidone results in increased expression of SREBF1 protein |
CTD |
PMID:20564506 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
EXP |
Risperidone inhibits the reaction [Rotenone results in decreased expression of STAT3 mRNA] |
CTD |
PMID:17442543 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Th |
tyrosine hydroxylase |
increases expression |
EXP |
Risperidone results in increased expression of TH protein |
CTD |
PMID:17028028 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
suvorexant inhibits the reaction [Morphine results in increased expression of CREB1 protein] |
CTD |
PMID:33609567 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
increases expression |
ISO |
suvorexant results in increased expression of GRIN2A protein |
CTD |
PMID:33609567 |
|
NCBI chr10:5,630,684...6,043,341
Ensembl chr10:5,631,369...6,044,637
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
suvorexant inhibits the reaction [Morphine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:33609567 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
suvorexant inhibits the reaction [Morphine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:33609567 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
|
G |
Ttr |
transthyretin |
multiple interactions |
ISO |
tafamidis promotes the reaction [TTR protein binds to TTR protein binds to TTR protein binds to TTR protein]; tafamidis results in increased stability of [TTR protein binds to TTR protein binds to TTR protein binds to TTR protein] |
CTD |
PMID:25595224 PMID:27093678 |
|
NCBI chr18:11,941,791...11,951,008
Ensembl chr18:11,943,789...11,951,008
|
|
|
G |
Car1 |
carbonic anhydrase 1 |
multiple interactions |
ISO |
zonisamide binds to and results in decreased activity of CA1 protein |
CTD |
PMID:17826101 |
|
NCBI chr 2:86,829,436...86,872,209
Ensembl chr 2:86,861,897...86,872,208
|
|
G |
Car2 |
carbonic anhydrase 2 |
multiple interactions |
ISO |
zonisamide binds to and results in decreased activity of CA2 protein |
CTD |
PMID:17826101 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
G |
Car3 |
carbonic anhydrase 3 |
multiple interactions |
ISO |
zonisamide binds to and results in decreased activity of CA3 protein |
CTD |
PMID:17826101 |
|
NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280
|
|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions |
EXP |
DRD1 protein promotes the reaction [zonisamide affects the secretion of Dopamine]; DRD1 protein promotes the reaction [zonisamide affects the secretion of gamma-Aminobutyric Acid] |
CTD |
PMID:19482038 |
|
NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
zonisamide inhibits the reaction [Tacrine results in increased expression of FOS protein] |
CTD |
PMID:18693129 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
ISO |
zonisamide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GFAP protein] |
CTD |
PMID:19199078 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Ifng |
interferon gamma |
decreases expression |
ISO |
zonisamide results in decreased expression of IFNG protein |
CTD |
PMID:10982153 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Maob |
monoamine oxidase B |
multiple interactions decreases activity |
ISO |
zonisamide inhibits the reaction [[MAOB protein results in increased metabolism of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] which results in increased chemical synthesis of 1-Methyl-4-phenylpyridinium]; zonisamide inhibits the reaction [Selegiline binds to MAOB protein] zonisamide results in decreased activity of MAOB protein |
CTD |
PMID:19948168 |
|
NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression |
EXP |
zonisamide results in increased expression of NOS2 mRNA |
CTD |
PMID:12429386 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Slc1a1 |
solute carrier family 1 member 1 |
increases expression |
EXP |
zonisamide results in increased expression of SLC1A1 protein |
CTD |
PMID:12941455 |
|
NCBI chr 1:226,549,932...226,631,925
Ensembl chr 1:226,549,842...226,630,402
|
|
G |
Th |
tyrosine hydroxylase |
increases expression multiple interactions |
ISO |
Zonisamide results in increased expression of TH mRNA; Zonisamide results in increased expression of TH protein zonisamide results in increased expression of TH protein [zonisamide co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] affects the activity of TH protein; zonisamide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein] |
CTD |
PMID:19199078 PMID:19948168 PMID:20196486 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
|
G |
Abcb6 |
ATP binding cassette subfamily B member 6 |
increases response to substance |
ISO |
ABCB6 gene mutant form results in increased susceptibility to Zoxazolamine |
CTD |
PMID:25623066 |
|
NCBI chr 9:76,668,554...76,677,263
Ensembl chr 9:76,668,554...76,676,924
|
|
G |
Ahr |
aryl hydrocarbon receptor |
affects response to substance |
ISO |
AHR protein affects the susceptibility to Zoxazolamine |
CTD |
PMID:2856069 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Ghrhr |
growth hormone releasing hormone receptor |
multiple interactions decreases response to substance |
ISO |
GHRHR protein affects the reaction [NR1I3 protein affects the susceptibility to Zoxazolamine] GHRHR gene mutant form results in decreased susceptibility to Zoxazolamine |
CTD |
PMID:17521389 |
|
NCBI chr 4:84,498,159...84,532,847
Ensembl chr 4:84,500,212...84,532,776
|
|
G |
Kcnn4 |
potassium calcium-activated channel subfamily N member 4 |
increases activity |
ISO |
Zoxazolamine results in increased activity of KCNN4 protein |
CTD |
PMID:14985237 |
|
NCBI chr 1:79,956,380...79,974,354
Ensembl chr 1:79,959,322...79,974,340
|
|
G |
Med1 |
mediator complex subunit 1 |
increases response to substance |
ISO |
MED1 gene mutant form results in increased susceptibility to Zoxazolamine |
CTD |
PMID:16109766 |
|
NCBI chr10:83,145,538...83,189,260
Ensembl chr10:83,145,568...83,189,299
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions increases response to substance affects response to substance |
ISO |
1,4-bis(2-(3,5-dichloropyridyloxy))benzene affects the reaction [NR1I3 affects the susceptibility to Zoxazolamine]; GHRHR protein affects the reaction [NR1I3 protein affects the susceptibility to Zoxazolamine]; nonylphenol affects the reaction [NR1I3 affects the susceptibility to Zoxazolamine]; NR1I3 protein affects the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in decreased susceptibility to Zoxazolamine] NR1I3 protein results in increased susceptibility to Zoxazolamine NR1I3 affects the susceptibility to Zoxazolamine; NR1I3 protein affects the susceptibility to Zoxazolamine |
CTD |
PMID:17483497 PMID:17521389 PMID:19041682 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|